Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668382 · ClinicalTrials.gov registry record · Phase 1
Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection
A Phase 1 study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT00668382: Completed Phase 1 study, sponsored by University of Massachusetts, Worcester.
NCT00668382 is a Phase 1 study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00668382, a Phase 1 study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.
Primary Outcome
Grade 3/4 Toxicity occurring in a participant within a month of intratumoral injection
Interventions
- BIOLOGICAL Alpha-Gal Glycosphingolipid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
What the finished NCT00668382 record still lists
NCT00668382 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Alpha-Gal Glycosphingolipid is the first listed.
NCT00668382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00668382 about?
NCT00668382 is a clinical study titled "Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection". This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.
What is the current status of trial NCT00668382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2007-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00668382?
The interventions under investigation include: Alpha-Gal Glycosphingolipid (BIOLOGICAL).
Who is sponsoring clinical trial NCT00668382?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00668382's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia